<DOC>
	<DOC>NCT00569764</DOC>
	<brief_summary>To measure the long-term changes in weight and plasma lipids after switching antipsychotic treatment to aripiprazole</brief_summary>
	<brief_title>Effect on Metabolic Parameters of Abilify in SPR</brief_title>
	<detailed_description>To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia. The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>DSMIV diagnosis with schizophrenia who signed an informed consent comorbid with substance abuse or substance dependence pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>aripiprazole</keyword>
</DOC>